Sofinnova Partners: €165M Biotech Acceleration Fund Closed
By Amit Chowdhry ● Yesterday at 6:34 PM
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova Biovelocita II. This fund has exceeded its target, successfully raising €165 million, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures.